Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
ConditionCancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNucMito Pharmaceuticals Co. Ltd.
About this trial
This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Advanced solid tumors (primarily advanced colorectal cancer or triple-negative breast cancer) confirmed by histology or cytology
Prior adequate standard therapy with documented progression or intolerance, or lack of available standard therapy options, or contraindications to standard therapy
At least one evaluable tumor lesion per RECIST version 1.1
Age 18 to 75 years at the time of informed consent
Disqualifiers
Known hypersensitivity to NM6603 or its components
Prior treatment with a drug targeting the same mechanism of action or molecular target
Participation in another drug or device clinical trial within 4 weeks before first dose
Major surgery within 4 weeks before first dose or planned surgery during the study
Trial design
Treatments tested in this trial
- NM6603
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov